



1707 U.S.PTO

021004

Please type a plus sign (+) inside this box → +

PTO/SB/05 (03-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. <b>VPI/00-130-07 DIV US</b>
		First Inventor <b>David Bebbington</b>
		Title <b>Pyrazole Compounds Useful as Protein Kinase Inhibitors</b>
		Express Mail Label No. <b>EV 317 172 250 US</b>

<b>APPLICATION ELEMENTS</b> <small>See MPEP chapter 600 concerning utility patent application contents.</small>		MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450
--	--	---

1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program ( <i>Appendix</i> )
2. <input type="checkbox"/> Applicant claims small entity status. <small>See 37 CFR 1.27.</small>	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <small>(if applicable, all necessary)</small>
3. <input checked="" type="checkbox"/> Specification <small>[Total Pages <b>87</b>]</small>  <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross Reference to Related Applications</li> <li>- Statement Regarding Fed sponsored R &amp; D</li> <li>- Reference to sequence listing, a table, or a computer program listing appendix</li> <li>- Background of the invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings (<i>if filed</i>)</li> <li>- Detailed Description</li> <li>- Claim(s)</li> <li>- Abstract of the Disclosure</li> </ul>	a. <input type="checkbox"/> Computer Readable Form (CRF)
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) <small>[Total Sheets <b>      </b>]</small>	b. <input type="checkbox"/> Specification Sequence Listing on: <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li> <li>ii. <input type="checkbox"/> paper</li> </ul>
5. Oath or Declaration <small>[Total Pages <b>4</b>]</small>	c. <input type="checkbox"/> Statements verifying identity of above copies
a. <input type="checkbox"/> UNEXECUTED DECLARATION (original or copy)	9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuation/divisional with Box 18 completed)</small>	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <small>(when there is an assignee)</small> <input type="checkbox"/> Power of Attorney
i. <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</small>	11. <input type="checkbox"/> English Translation Document ( <i>if applicable</i> )
6. <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	12. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:	13. <input checked="" type="checkbox"/> Preliminary Amendment
<input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: <b>10/034,019</b>	14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small>
Prior application information: Examiner <b>Tamthorn Ngo Truong</b> Group / Art Unit: <b>1624</b>	15. <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small>
For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	

<b>19. CORRESPONDENCE ADDRESS</b>					
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		<b>27916</b>		or <input type="checkbox"/> Correspondence address below	
Name	Andrea L. C. Robidoux Vertex Pharmaceuticals Incorporated				
Address	130 Waverly Street				
City	Cambridge	State	Massachusetts	Zip Code	02139-4242
Country	USA	Telephone	(617) 444-6731	Fax	(617) 444-6483
Name (Print/Type)	Andrea L. C. Robidoux		Registration No. (Attorney/Agent)	47,902	
Signature				Date	February 10, 2004

10/775696 U.S.PTO  
22390 021004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>FEE TRANSMITTAL</b> <b>for FY 2004</b>		<b>Complte if Known</b>			
Patent fees are subject to annual revision.		Application Number      Not Yet Assigned Filing Date              February 10, 2004 First Named Inventor    David Bebbington Examiner Name           Tamthom Ngo Truong Group Art Unit           1624 Attorney Docket No.     VPI/00-130-07 DIV US			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27					
<b>TOTAL AMOUNT OF PAYMENT</b>		(\$ 1,060.00)			
<b>METHOD OF PAYMENT</b> (check all that apply)					
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None <input checked="" type="checkbox"/> Deposit Account					
Deposit Account Number		50-0725			
Deposit Account Name		Vertex Pharmaceuticals			
The Commissioner is hereby authorized to: (check all that apply) <input checked="" type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.					
<b>FEE CALCULATION</b>					
<b>1. BASIC FILING FEE</b>					
Large Entity		Small Entity			
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)		(\$ 770.00)			
<b>2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE</b>					
Total Claims		Extra Claims	Fee from below	Fee Paid	
21		-20** =	0 x 18.00	= 0.00	
Independent Claims		2 -3** =	0 x 86.00	= 0.00	
Multiple Dependent			290.00	= 290.00	
Large Entity		Small Entity			
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)		(\$ 290.00)			
**or number previously paid, if greater; For Reissues, see above					
*Reduced by Basic Filing Fee Paid					
SUBTOTAL (3) (\$ 0.00)					
Complete (if applicable)					
SUBMITTED BY					
Name (Print/Type)	Andrea L. C. Robidoux		Registration No. (Attorney/Agent)	47,902	Telephone (617) 444-6731
Signature				Date	February 10, 2004

**Certificate Of Mailing Under 37 C.F.R. § 1.10**

Express Mailing No. EV 317 172 250 US Date of Deposit: February 10, 2004

I hereby certify that the following documents:

1. Utility Transmittal for Patent Application (1 page);
2. Fee Transmittal (1 page, in duplicate);
3. Information Disclosure Statement (2 pages, in duplicate);
4. PTO-1449 Form (1 page, in duplicate);
5. Specification: 87 pages (Desc. 71 pgs, Claims 15 pgs., Abstract 1 pg); and
6. Copy of executed Declaration and Power of Attorney document (4 pages);
7. Return postcard receipt.

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

---

Karen DiRocco

(type or printed name of person mailing document(s))

---



(signature of person mailing document(s))